116 related articles for article (PubMed ID: 36905212)
1. PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer.
Li B; Zhang J; Ma N; Li W; You G; Chen G; Zhao L; Wang Q; Zhou H
Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):120-130. PubMed ID: 36905212
[TBL] [Abstract][Full Text] [Related]
2. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
3. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Inhibitor Combined with Chemotherapeutic Agents for Antitumor and Antimetastatic Efficacy against Osteosarcoma.
Zhao TT; Zhou TJ; Zhang C; Liu YX; Wang WJ; Li C; Xing L; Jiang HL
Mol Pharm; 2023 May; 20(5):2612-2623. PubMed ID: 37042832
[TBL] [Abstract][Full Text] [Related]
5. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.
Kim YJ; Lee HJ; Kim TM; Eisinger-Mathason TS; Zhang AY; Schmidt B; Karl DL; Nakazawa MS; Park PJ; Simon MC; Yoon SS
Int J Cancer; 2013 Jan; 132(1):29-41. PubMed ID: 22684860
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
8. The effect of HIF-1α inhibition in breast cancer cells prior to doxorubicin treatment under conditions of normoxia and hypoxia.
Fourie C; du Plessis M; Mills J; Engelbrecht AM
Exp Cell Res; 2022 Oct; 419(2):113334. PubMed ID: 36044939
[TBL] [Abstract][Full Text] [Related]
9. Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells.
Das S; Filippone SM; Williams DS; Das A; Kukreja RC
Mol Cell Biochem; 2016 Oct; 421(1-2):89-101. PubMed ID: 27565811
[TBL] [Abstract][Full Text] [Related]
10. Preparation and In Vitro and In Vivo Antitumor Effects of VEGF Targeting Micelles.
Chang J; Yang Z; Li J; Jin Y; Gao Y; Sun Y; Li H; Yu T
Technol Cancer Res Treat; 2020; 19():1533033820957022. PubMed ID: 32912078
[TBL] [Abstract][Full Text] [Related]
11. HBOC alleviated tumour hypoxia during radiotherapy more intensely in large solid tumours than regular ones.
Xu Y; Zhu K; Wu J; Zheng S; Zhong R; Zhou W; Cao Y; Liu J; Wang H
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):1-14. PubMed ID: 37994792
[TBL] [Abstract][Full Text] [Related]
12. Nanodelivery of doxorubicin for age-related macular degeneration.
Kelly SJ; Halasz K; Smalling R; Sutariya V
Drug Dev Ind Pharm; 2019 May; 45(5):715-723. PubMed ID: 30704311
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
[TBL] [Abstract][Full Text] [Related]
14. A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells.
Wang L; Zhang X; Chan JY; Shan L; Cui G; Cui Q; Wang Y; Li J; Chen H; Zhang Q; Yu P; Han Y; Wang Y; Lee SM
J Cell Biochem; 2016 Jan; 117(1):94-105. PubMed ID: 26058377
[TBL] [Abstract][Full Text] [Related]
15. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
[TBL] [Abstract][Full Text] [Related]
17. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
Pawar S; Mahajan K; Vavia P
AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
[TBL] [Abstract][Full Text] [Related]
19. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.
Lu Y; Zhang S; Zhu X; Wang K; He Y; Liu C; Sun J; Pan J; Zheng L; Liu W; Li Y; Huang Y; Liu T
J Ethnopharmacol; 2023 Mar; 303():115968. PubMed ID: 36473617
[TBL] [Abstract][Full Text] [Related]
20. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
